Systemic Evaluation of Gefitinib in the Treatment of Non-small-cell Lung Cancer_Chinese Journal of Evidence-Based Medicine

Authors：

 XU Fenghua , GUO Rongrong , SUN Huayan

Department of Pharmaceutical Care, PLA General Hospital, Beijing 100853, China;

Corresponding author：

XU Fenghua, Email: xufh@yahoo.com

Keywords：

Non-small-cell lung cancer; Gefinitib; Treatment; Meta analysis

DOI：

10.7507/1672-2531.20090044

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To evaluate the efficacy of Gefitinib for patients with non-small-cell lung cancer (NSCLC).
Methods 　We searched several databases, including MEDLINE (1991 to June 2008), The Cochrane Library (Issue 4, 2008) and CBMDisc (1978 to Feb. 2008). Randomized controlled trials (RCTs) were included in the meta-analyses, which were done using The Cochrane Collaboration’s RevMan 4.2 software. We also included retrospective case reports published in Chinese journals.
Results 　Eight RCTs and 36 uncontrolled case reports were analyzed. The results of the RCTs showed that 250 mg/d Gefitinib had similar efficacy to 500 mg/d, but the side effect was significantly less for the lower dose. When used as a combined first-line treatment or a third-line treatment, Gefitinib was not superior to placebo on response rate, survival rate and life span. When used as second-line treatment, it did not prolong median survival, though it gave a higher response rate than placebo. Gefitinib caused many more side effects than placebo. Gefitinib exhibited similar efficacy to docetaxel in objective response rate [OR 1.18, 95%CI (0.84, 1.67), P=0.35], but was better for symptom and quality-of-life improvement [OR 1.58, 95%CI (1.33, 1.89), P lt;0.00001]. The overall uncontrolled clinical studies showed the following results: complete response rate was 2.2%, partial response rate was 25.8%, disease stable rate was 40.0% and progressive disease rate was 32.0%. The average median survival time was 8.9 months; the average time to progressive disease was 5.2 months, and the 1-year survival rate was 44.2%. The average median survival from EAP studies (6.9 months) was shorter than that for all the studies as well as the registered clinical trials (10.0 months). The average periods to progressive disease for registered clinical trials (3.2 months) and EAP studies (4.4 months) were somewhat shorter than that found for all studies combined, though response rate and 1-year survival rate were similar. Since there was no controlled clinical study, it was hard to conclude from the results whether Gefitinib brought any clinical benefit to NSCLC patients in China.
Conclusion 　 Gifitinib is not suitable as a combined first-line treatment or a third-line treatment for NSCLC. The clinical favor from gefitinib in the second-line treatment remains uncertain. There is not enough evidence to show whether Chinese people are more sensitive to Gefitinib, and its use in the second-line treatment of NSCLC needs to be tested further.

Citation： XU Fenghua,GUO Rongrong,SUN Huayan. Systemic Evaluation of Gefitinib in the Treatment of Non-small-cell Lung Cancer. Chinese Journal of Evidence-Based Medicine, 2009, 09(2): 218-229. doi: 10.7507/1672-2531.20090044 Copy

1.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2.	Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer, 2004, 90(11): 2157-2166.
3.	Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med, 2004, 25 Suppl 1: 3-10.
4.	乔贵宾, 吴一龙. 酪氨酸激酶受体信号传导通路与肺癌的靶向治疗. 中国处方药, 2005, 5(38): 14-17.
5.	杨学宁, 吴一龙. 口服小分子靶向治疗药物吉非替尼. 临床药物治疗杂志, 2005, 3(2): 56-59.
6.	Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol, 2003, 21(12): 2237-2246.
7.	Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290(16): 2149-2158.
8.	Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol, 2004, 22(5): 777-784.
9.	Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol, 2004, 22(5): 785-794.
10.	Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(9496): 1527-1537.
11.	Kelly K, Chansky K, Gaspar LE, et al. Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small- Cell Lung Cancer: SWOG S0023. J Clin Oncology, 2008, 26(15): 2450-2456.
12.	Cufer T, Vrdoljak E, Gaafar R, et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs, 2006, 17(4): 401-9.
13.	Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
14.	管忠震, 张力, 李龙芸, 等. 吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究. 癌症, 2005, 24(8): 980-984.
15.	张阳, 张力, 徐菲, 等. 吉非替尼记名供药计划(EAP)治疗晚期非小细胞肺癌患者的临床研究结果. 癌症, 2006, 25(12): 1561-1564.
16.	张康, 左强, 罗荣城. 吉非替尼治疗36例晚期非小细胞肺癌. 中国癌症杂志, 2006, 16(10): 878-879.
17.	谢晓冬, 郑振东, 刘大为, 等. 吉非替尼(Iressa)治疗晚期复治非小细胞肺癌的临床观察. 中国肿瘤临床, 2006, 33(10): 574-576.
18.	徐建明, 李月敏, 刘晓晴, 等. 吉非替尼治疗晚期非小细胞肺癌的临床研究. 中华肿瘤杂志, 2007, 29(1): 66-69.
19.	张品良, 陈黎. 吉非替尼治疗晚期非小细胞肺癌53例临床观察. 临床肿瘤学杂志, 2006, 11(9): 690-693.
20.	王彬, 张湘茹, 储大同. 易瑞沙在晚期非小细胞肺癌化疗失败后的作用. 中华肿瘤杂志, 2004, 26(12): 742-745.
21.	刘莹, 谢小云. 单用吉非替尼对非小细胞肺癌的疗效评价. 中国医院药学杂志, 2007, 27(7): 924-926.
22.	谢晓冬, 郑振东, 屈叔贤, 等. 吉非替尼治疗非小细胞肺癌51例疗效观察. 沈阳部队医药, 2007, 20(4): 247-249.
23.	郑迪, 山鸟忠宏, 平岛智德, 等. 吉非替尼单药治疗化疗失败的晚期非小细胞肺癌31例. 中国新药杂志, 2004, 13(6): 553-555.
24.	张翠英, 杨宏, 陈彦俊. 吉非替尼治疗晚期非小细胞肺癌32例. 内蒙古医学杂志, 2007, 39(4): 439-441.
25.	霍伟, 冯仲珉, 赵卫红, 等. 吉非替尼治疗晚期非小细胞肺癌64例. 临床肿瘤学杂志, 2005, 10(1): 4-7.
26.	冯仲珉, 刘艳娥, 孙利敏. 吉非替尼治疗晚期非小细胞肺癌的临床研究. 大连医科大学学报, 2007, 29(6): 546-549.
27.	郑航, 陈锦章, 罗荣城. 吉非替尼治疗晚期非小细胞肺癌的临床研究. 临床肿瘤学杂志, 2006, 11(10): 744-746.
28.	吴凤坚, 陈广幸, 汪森明, 等. 吉非替尼治疗晚期非小细胞肺癌疗效观察. 现代医药卫生, 2006, 22(21): 3293-3294.
29.	张晓彤, 李龙芸, 王树兰, 等. 吉非替尼治疗晚期非小细胞肺癌疗效观察. 中华结核和呼吸杂志, 2005, 28(3): 180-183.
30.	徐艳霞, 徐媺, 高炜. 吉非替尼治疗晚期复治的非小细胞肺癌的临床观察. 药物与临床, 2007, 4(14): 48-49.
31.	林琳, 王彬, 张湘茹, 等. 易瑞沙在24 例化疗后进展的晚期非小细胞肺癌中的作用. 中国肺癌杂志, 2006, 9(3): 280-282.
32.	王巍, 邓燕明, 胡斌. 易瑞沙治疗化疗失败的晚期非小细胞肺癌. 实用癌症杂志, 2007, 22(6): 614-616.
33.	凌扬, 徐建忠, 杨全良, 等. 易瑞沙治疗化疗失败非小细胞肺癌的临床观察. 肿瘤防治杂志, 2005, 12(18): 1413-1414.　.
34.	周浩本, 周世繁, 王居峰, 等. 易瑞沙治疗晚期非小细胞肺癌临床观察. 中华肿瘤防治杂志, 2006, 13(22): 1759.
35.	郑华, 王敬萍. 吉非替尼（Iressa）在晚期肺腺癌的靶向治疗疗效观察. 中国肺癌杂志, 2007, 10(3): 229-233.
36.	张莉, 于世英. 吉非替尼单药治疗晚期非小细胞肺癌. 中华肿瘤杂志, 2006, 28(7): 539-541.
37.	夏国豪, 史美祺, 江伟, 等. 吉非替尼治疗化疗失败的晚期非小细胞肺癌38例. 肿瘤基础与临床, 2007, 20(5): 390-392.
38.	张志豪, 杜开齐, 朱有才, 等. 吉非替尼治疗23例晚期非小细胞肺癌. 中国癌症杂志, 2007, 17(11): 894-896.
39.	杨鹭, 刘叙仪, 方健, 等. 吉非替尼治疗91例晚期非小细胞肺癌疗效分析. 中国肿瘤杂志, 2006, 28(6): 474-477.
40.	温浙盛, 陈晓勤, 吴海鹰, 等. 吉非替尼治疗不同类型晚期非小细胞肺癌患者的疗效比较. 癌症, 2007, 26(4): 415-417.
41.	张燕, 陈黎, 张品良, 等. 吉非替尼治疗难治性非小细胞肺癌的疗效. 中国新药与临床杂志, 2006, 25(3): 196-199.
42.	贾国强, 杨亚青. 吉非替尼治疗非小细胞肺癌的临床疗效观察. 药学实践杂志, 2007, 25(6): 399-400.
43.	王燕, 王颖, 王彬, 等. 吉非替尼治疗非小细胞肺癌脑转移的初步结果. 中国肺癌杂志, 2006, 9(5): 447-451.
44.	郭宇玲, 孙哲, 李艳茹. 吉非替尼治疗复治晚期非小细胞肺腺癌12例. 肿瘤学杂志, 2006, 12(6): 512.
45.	吕蕾, 缪建华, 陈暑波, 等. 吉非替尼联合艾迪治疗老年非小细胞肺癌的临床研究. 齐齐哈尔医学院学报, 2006, 27(17): 2057-2059.
46.	钱军, 秦叔逵, 杨柳青, 等. 吉非替尼联合康莱特治疗中晚期非小细胞肺癌的临床研究. 临床肿瘤学杂志, 2004, 9(6): 568-570.
47.	苏安, 吕霞, 王馨, 等. 吉非替尼与多烯紫杉醇二线治疗Ⅳ期肺腺癌疗效比较. 实用癌症杂志, 2007, 22(6): 617-619.
48.	孙利敏. 吉非替尼改善晚期非小细胞肺癌患者生活质量的临床分析. 大连医科大学学报, 2007, 29(5): 483-490.
49.	胡洪林, 邓颖, 任刚, 等. 吉非替尼治疗晚期非小细胞肺癌临床疗效分析. 实用医院临床杂志, 2007, 4(5): 36-38.
50.	Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol, 2008, 3(4): 430-440.
51.	郭荣荣, 徐风华, 孙华燕. 多烯紫杉醇作为晚期非小细胞肺癌的二线治疗药物的系统评价. 中国循证医学杂志, 2008, 8(10): 861-868.
52.	Parikh P, Chang AY, Nag S, et al. Clinical experience with gefitinib in Indian patients. J Thorac Oncol, 2008, 3(4): 380-385.
53.	Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol, 2007, 2(5): 430-439.
54.	Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol, 2006, 24(31): 5034-5042.
55.	Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
56.	潘振奎, 张力, 张星, 等. 中国非小细胞肺癌患者表皮生长因子受体突变的研究. 癌症, 2005, 24(8): 919-923.

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2. Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer, 2004, 90(11): 2157-2166.
3. Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med, 2004, 25 Suppl 1: 3-10.
4. 乔贵宾, 吴一龙. 酪氨酸激酶受体信号传导通路与肺癌的靶向治疗. 中国处方药, 2005, 5(38): 14-17.
5. 杨学宁, 吴一龙. 口服小分子靶向治疗药物吉非替尼. 临床药物治疗杂志, 2005, 3(2): 56-59.
6. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol, 2003, 21(12): 2237-2246.
7. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290(16): 2149-2158.
8. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol, 2004, 22(5): 777-784.
9. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol, 2004, 22(5): 785-794.
10. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(9496): 1527-1537.
11. Kelly K, Chansky K, Gaspar LE, et al. Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small- Cell Lung Cancer: SWOG S0023. J Clin Oncology, 2008, 26(15): 2450-2456.
12. Cufer T, Vrdoljak E, Gaafar R, et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs, 2006, 17(4): 401-9.
13. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
14. 管忠震, 张力, 李龙芸, 等. 吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究. 癌症, 2005, 24(8): 980-984.
15. 张阳, 张力, 徐菲, 等. 吉非替尼记名供药计划(EAP)治疗晚期非小细胞肺癌患者的临床研究结果. 癌症, 2006, 25(12): 1561-1564.
16. 张康, 左强, 罗荣城. 吉非替尼治疗36例晚期非小细胞肺癌. 中国癌症杂志, 2006, 16(10): 878-879.
17. 谢晓冬, 郑振东, 刘大为, 等. 吉非替尼(Iressa)治疗晚期复治非小细胞肺癌的临床观察. 中国肿瘤临床, 2006, 33(10): 574-576.
18. 徐建明, 李月敏, 刘晓晴, 等. 吉非替尼治疗晚期非小细胞肺癌的临床研究. 中华肿瘤杂志, 2007, 29(1): 66-69.
19. 张品良, 陈黎. 吉非替尼治疗晚期非小细胞肺癌53例临床观察. 临床肿瘤学杂志, 2006, 11(9): 690-693.
20. 王彬, 张湘茹, 储大同. 易瑞沙在晚期非小细胞肺癌化疗失败后的作用. 中华肿瘤杂志, 2004, 26(12): 742-745.
21. 刘莹, 谢小云. 单用吉非替尼对非小细胞肺癌的疗效评价. 中国医院药学杂志, 2007, 27(7): 924-926.
22. 谢晓冬, 郑振东, 屈叔贤, 等. 吉非替尼治疗非小细胞肺癌51例疗效观察. 沈阳部队医药, 2007, 20(4): 247-249.
23. 郑迪, 山鸟忠宏, 平岛智德, 等. 吉非替尼单药治疗化疗失败的晚期非小细胞肺癌31例. 中国新药杂志, 2004, 13(6): 553-555.
24. 张翠英, 杨宏, 陈彦俊. 吉非替尼治疗晚期非小细胞肺癌32例. 内蒙古医学杂志, 2007, 39(4): 439-441.
25. 霍伟, 冯仲珉, 赵卫红, 等. 吉非替尼治疗晚期非小细胞肺癌64例. 临床肿瘤学杂志, 2005, 10(1): 4-7.
26. 冯仲珉, 刘艳娥, 孙利敏. 吉非替尼治疗晚期非小细胞肺癌的临床研究. 大连医科大学学报, 2007, 29(6): 546-549.
27. 郑航, 陈锦章, 罗荣城. 吉非替尼治疗晚期非小细胞肺癌的临床研究. 临床肿瘤学杂志, 2006, 11(10): 744-746.
28. 吴凤坚, 陈广幸, 汪森明, 等. 吉非替尼治疗晚期非小细胞肺癌疗效观察. 现代医药卫生, 2006, 22(21): 3293-3294.
29. 张晓彤, 李龙芸, 王树兰, 等. 吉非替尼治疗晚期非小细胞肺癌疗效观察. 中华结核和呼吸杂志, 2005, 28(3): 180-183.
30. 徐艳霞, 徐媺, 高炜. 吉非替尼治疗晚期复治的非小细胞肺癌的临床观察. 药物与临床, 2007, 4(14): 48-49.
31. 林琳, 王彬, 张湘茹, 等. 易瑞沙在24 例化疗后进展的晚期非小细胞肺癌中的作用. 中国肺癌杂志, 2006, 9(3): 280-282.
32. 王巍, 邓燕明, 胡斌. 易瑞沙治疗化疗失败的晚期非小细胞肺癌. 实用癌症杂志, 2007, 22(6): 614-616.
33. 凌扬, 徐建忠, 杨全良, 等. 易瑞沙治疗化疗失败非小细胞肺癌的临床观察. 肿瘤防治杂志, 2005, 12(18): 1413-1414.　.
34. 周浩本, 周世繁, 王居峰, 等. 易瑞沙治疗晚期非小细胞肺癌临床观察. 中华肿瘤防治杂志, 2006, 13(22): 1759.
35. 郑华, 王敬萍. 吉非替尼（Iressa）在晚期肺腺癌的靶向治疗疗效观察. 中国肺癌杂志, 2007, 10(3): 229-233.
36. 张莉, 于世英. 吉非替尼单药治疗晚期非小细胞肺癌. 中华肿瘤杂志, 2006, 28(7): 539-541.
37. 夏国豪, 史美祺, 江伟, 等. 吉非替尼治疗化疗失败的晚期非小细胞肺癌38例. 肿瘤基础与临床, 2007, 20(5): 390-392.
38. 张志豪, 杜开齐, 朱有才, 等. 吉非替尼治疗23例晚期非小细胞肺癌. 中国癌症杂志, 2007, 17(11): 894-896.
39. 杨鹭, 刘叙仪, 方健, 等. 吉非替尼治疗91例晚期非小细胞肺癌疗效分析. 中国肿瘤杂志, 2006, 28(6): 474-477.
40. 温浙盛, 陈晓勤, 吴海鹰, 等. 吉非替尼治疗不同类型晚期非小细胞肺癌患者的疗效比较. 癌症, 2007, 26(4): 415-417.
41. 张燕, 陈黎, 张品良, 等. 吉非替尼治疗难治性非小细胞肺癌的疗效. 中国新药与临床杂志, 2006, 25(3): 196-199.
42. 贾国强, 杨亚青. 吉非替尼治疗非小细胞肺癌的临床疗效观察. 药学实践杂志, 2007, 25(6): 399-400.
43. 王燕, 王颖, 王彬, 等. 吉非替尼治疗非小细胞肺癌脑转移的初步结果. 中国肺癌杂志, 2006, 9(5): 447-451.
44. 郭宇玲, 孙哲, 李艳茹. 吉非替尼治疗复治晚期非小细胞肺腺癌12例. 肿瘤学杂志, 2006, 12(6): 512.
45. 吕蕾, 缪建华, 陈暑波, 等. 吉非替尼联合艾迪治疗老年非小细胞肺癌的临床研究. 齐齐哈尔医学院学报, 2006, 27(17): 2057-2059.
46. 钱军, 秦叔逵, 杨柳青, 等. 吉非替尼联合康莱特治疗中晚期非小细胞肺癌的临床研究. 临床肿瘤学杂志, 2004, 9(6): 568-570.
47. 苏安, 吕霞, 王馨, 等. 吉非替尼与多烯紫杉醇二线治疗Ⅳ期肺腺癌疗效比较. 实用癌症杂志, 2007, 22(6): 617-619.
48. 孙利敏. 吉非替尼改善晚期非小细胞肺癌患者生活质量的临床分析. 大连医科大学学报, 2007, 29(5): 483-490.
49. 胡洪林, 邓颖, 任刚, 等. 吉非替尼治疗晚期非小细胞肺癌临床疗效分析. 实用医院临床杂志, 2007, 4(5): 36-38.
50. Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol, 2008, 3(4): 430-440.
51. 郭荣荣, 徐风华, 孙华燕. 多烯紫杉醇作为晚期非小细胞肺癌的二线治疗药物的系统评价. 中国循证医学杂志, 2008, 8(10): 861-868.
52. Parikh P, Chang AY, Nag S, et al. Clinical experience with gefitinib in Indian patients. J Thorac Oncol, 2008, 3(4): 380-385.
53. Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol, 2007, 2(5): 430-439.
54. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol, 2006, 24(31): 5034-5042.
55. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
56. 潘振奎, 张力, 张星, 等. 中国非小细胞肺癌患者表皮生长因子受体突变的研究. 癌症, 2005, 24(8): 919-923.

Chinese Journal of Evidence-Based Medicine

Systemic Evaluation of Gefitinib in the Treatment of Non-small-cell Lung Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content